CN114728932A - 作为egfr激酶抑制剂的多芳基化合物 - Google Patents

作为egfr激酶抑制剂的多芳基化合物 Download PDF

Info

Publication number
CN114728932A
CN114728932A CN202080081283.0A CN202080081283A CN114728932A CN 114728932 A CN114728932 A CN 114728932A CN 202080081283 A CN202080081283 A CN 202080081283A CN 114728932 A CN114728932 A CN 114728932A
Authority
CN
China
Prior art keywords
compound
amino
formula
methoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080081283.0A
Other languages
English (en)
Inventor
刘磊
刘扬
周峰
唐任宏
任晋生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of CN114728932A publication Critical patent/CN114728932A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

本发明涉及作为***(T790M/C797S突变)EGFR激酶抑制剂及其医药用途，具体公开了式(I)所示化合物或其药学上可接受的盐。本发明化合物在EGFR Del19/T790M/C797S和L858R/T790M/C797S异常突变引起的疾病上有着较好的疗效。

Description

PCT国内申请，说明书已公开。

Claims (36)

  1. PCT国内申请，权利要求书已公开。
CN202080081283.0A 2019-11-29 2020-11-27 作为egfr激酶抑制剂的多芳基化合物 Pending CN114728932A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201911205549 2019-11-29
CN2019112055493 2019-11-29
CN202010063931 2020-01-20
CN2020100639311 2020-01-20
CN2020105238613 2020-06-10
CN202010523861 2020-06-10
PCT/CN2020/132188 WO2021104441A1 (zh) 2019-11-29 2020-11-27 作为egfr激酶抑制剂的多芳基化合物

Publications (1)

Publication Number Publication Date
CN114728932A true CN114728932A (zh) 2022-07-08

Family

ID=76129129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081283.0A Pending CN114728932A (zh) 2019-11-29 2020-11-27 作为egfr激酶抑制剂的多芳基化合物

Country Status (2)

Country Link
CN (1) CN114728932A (zh)
WO (1) WO2021104441A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022262857A1 (zh) * 2021-06-17 2022-12-22 微境生物医药科技(上海)有限公司 芳基氧膦类化合物
CN117769560A (zh) * 2021-08-19 2024-03-26 贝达药业股份有限公司 Egfr抑制剂的盐、晶型及其组合物和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105150A (zh) * 2008-05-21 2011-06-22 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
CN103153064A (zh) * 2010-10-14 2013-06-12 阿里亚德医药股份有限公司 抑制egfr导致的癌症中细胞增殖的方法
CN103501612A (zh) * 2011-05-04 2014-01-08 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020216371A1 (zh) * 2019-04-26 2020-10-29 江苏先声药业有限公司 Egfr抑制剂及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105150A (zh) * 2008-05-21 2011-06-22 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
CN103153064A (zh) * 2010-10-14 2013-06-12 阿里亚德医药股份有限公司 抑制egfr导致的癌症中细胞增殖的方法
CN103501612A (zh) * 2011-05-04 2014-01-08 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2019015655A1 (zh) * 2017-07-19 2019-01-24 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的芳基磷氧化合物

Also Published As

Publication number Publication date
WO2021104441A1 (zh) 2021-06-03

Similar Documents

Publication Publication Date Title
TW202140458A (zh) 螺環四氫喹唑啉
KR20160116033A (ko) 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물
CN114502536A (zh) 作为激酶抑制剂的杂环化合物
CN113801114A (zh) 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用
EP3640247B1 (en) Syk inhibitor and use method therefor
CN114845711A (zh) Raf激酶的抑制剂
WO2015144799A1 (en) SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS
KR101745741B1 (ko) 신규한 트리아졸로 피라진 유도체 및 그의 용도
WO2013016999A1 (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
CN114728932A (zh) 作为egfr激酶抑制剂的多芳基化合物
CN113330009A (zh) 氮杂环化合物、其制备方法及用途
CN117858872A (zh) 用于治疗癌症的杂环egfr抑制剂
TW202231633A (zh) Cdk抑制劑
CN112094269B (zh) 一类饱和六元环并杂环类化合物、制备方法和用途
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
CN113968856A (zh) 一类具有激酶抑制活性的化合物
WO2023107552A2 (en) Purines and methods of their use
TW202325300A (zh) 稠合醯亞胺類衍生物及其應用
WO2021244502A1 (zh) 多芳基化合物及应用
CN114805361A (zh) 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
WO2021247862A1 (en) Bicyclic heteroarenes and methods of their use
WO2022093881A1 (en) N-linked isoquinoline amides as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
KR20240041354A (ko) 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도
CN115151551A (zh) 作为mcl-1抑制剂的大环吲哚衍生物
WO2023107623A2 (en) Bicyclic heteroarenes and methods of their use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination